Michael Moore, DO
Interventional Cardiology · Spring Hill, FLNPI 1831184456
Payments from drug & device makers
What this record shows
This record is dominated by other: $20,000 of the $26,545 with a category attached, or 75.3%. Angiodynamics, Inc. accounts for 75.3% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $11,904 and has fallen 88.6% since, to $1,356 in 2025.
Across 158 payments — averaging $168.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$20K
- Medtronic$2K
- Boston Scientific$1K
- Edwards Lifesciences$915
- Abiomed$830
- Astellas Pharma US Inc$216
- plus $1K from 17 others
Across 28 payments — averaging $179.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$5K
What the payments were for
- Travel & lodging$1,8777%
- Food & beverage$4,46917%
- Education$1981%
- Other$20,00075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $20,000 |
| Medtronic(2 entities) | 34 | $2,037 |
| Boston Scientific | 56 | $1,416 |
| Edwards Lifesciences | 6 | $915 |
| Abiomed | 9 | $830 |
| Astellas Pharma US Inc | 3 | $216 |
| Bolton Medical Inc | 1 | $168 |
| Shockwave Medical, Inc | 1 | $162 |
| Novartis | 8 | $140 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $136 |
| Kestra Medical Technology Services, Inc. | 3 | $87 |
| Johnson & Johnson | 5 | $78 |
| Boehringer Ingelheim | 4 | $74 |
| Abbott | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Amgen | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Bayer | 1 | $29 |
| Cook Medical LLC | 1 | $21 |
| Lundbeck LLC | 1 | $14 |
| Pfizer | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Cardiovascular Systems Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,545 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 554 | $584,507 |
| XareltoRivaroxaban | 110 | $115,891 |
| FarxigaDapagliflozin Propanediol | 72 | $75,574 |
| JardianceEmpagliflozin | 40 | $62,023 |
| EntrestoSacubitril/Valsartan | 54 | $60,487 |
| Repatha SureclickEvolocumab | 57 | $44,268 |
| MultaqDronedarone Hcl | 16 | $19,185 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 28 | $8,644 |
| Flecainide Acetate | 142 | $7,231 |
| Praluent PenAlirocumab | 12 | $6,900 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $6,553 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 165 | $6,245 |
| VascepaIcosapent Ethyl | 18 | $6,123 |
| ClopidogrelClopidogrel Bisulfate | 422 | $6,010 |
| Ranolazine ErRanolazine | 52 | $5,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $584,507554 claims |
| Johnson & JohnsonXarelto | $78 | $115,891110 claims |
| AstraZenecaFarxiga | $12 | $75,57472 claims |
| Boehringer IngelheimJardiance | $74 | $62,02340 claims |
| NovartisEntresto | $140 | $60,48754 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Spring Hill
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.